Skip to content
value.today
Corbus Pharmaceuticals Holdings, Inc. logo

Corbus Pharmaceuticals Holdings, Inc.

CRBP
$92 Mmarket cap on Oct 20, 2026+228.3% since Jan 2024
Compare
World rank
#19,059
Revenue
—
For year ending December-2025
Net income
$-79 M
SEC filing
Employees
36
As of December 31, 2025
SEC filing

Corbus Pharmaceuticals Holdings, Inc. in brief

Corbus Pharmaceuticals Holdings, Inc. is a listed company in the Biotechnology industry, based in Norwood, Massachusetts, USA. It was founded in 2009. Its market value was $92 M on 20 October 2026, which makes it the 19,059th largest listed company in the world and the 3,557th largest in the USA on this site. It employs about 36 people and Yuval Cohen is its chief executive. Its shares trade under the symbol CRBP (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Corbus Pharmaceuticals Holdings, Inc.

Corbus Pharmaceuticals Holdings, Inc. is a clinical stage company focused on promising new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing innovative scientific approaches to well-understood biological pathways. Corbus’ pipeline includes CRB-701, a next-generation antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E and CRB-913, a highly peripherally restricted cannabinoid type-1 receptor inverse agonist for the treatment of obesity.

CRB-701 (SYS6002) is a novel clinical stage ADC that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of MMAE. In February 2023, the Company obtained a license from CSPC Megalith Biopharmaceutical Co. Ltd., a subsidiary of CSPC Pharmaceutical Group Limited, to develop and commercialize the drug in the United States, Canada, the European Union (including the European Free Trade Area), the United Kingdom and Australia. The Company is conducting a Phase 1/2 study in the U.S. and Europe enrolling patients with advanced solid tumors associated with Nectin-4 expression. The dose expansion phase of the clinical trial is ongoing. In June 2025, the Company began dosing participants in the PD-1 combination arm with CRB-701 in combination with Keytruda® (pembrolizumab). The Company has received fast track designation for CRB-701 from the U.S. Food and Drug Administration for the treatment of relapsed or refractory metastatic cervical cancer in December 2024 and in recurrent or metastatic head and neck squamous cell carcinoma previously treated with platinum-based chemotherapy and an anti-PD(L)-1 therapy in September 2025. CRB-701 is currently being investigated by CSPC in a Phase 3 clinical trial in patients with cervical cancer in China.

From the company's annual report filed with the US SEC: read the report

Corbus Pharmaceuticals Holdings, Inc. timeline

4 events, 2009–2018
  1. 2009
  2. 🏁
    Founded
  3. 2014
  4. ✎
    Renamed Corbus Pharmaceuticals Holdings, Inc.
    Formerly SAV Acquisition Corp.
  5. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  6. 2018
  7. •
    Legal Entity Identifier issued
    LEI 529900MX6XCNZC7MM155 registered.

Events of Corbus Pharmaceuticals Holdings, Inc. from Wikidata, SEC EDGAR and the GLEIF LEI register. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$96 M$191 M$287 M$382 M2020202120222023202420252026

World rank over time

▼ down 6,197 places since 2020
2020-01-01: #12900#12,90020202021-01-01: #17929#17,92920212022-01-07: #24645#24,64520222022-12-25: #30314#30,31420222023-07-30: #27920#27,92020232024-01-05: #27572#27,57220242026-03-08: #9495#9,49520262026-08-01: #15491#15,49120262026-10-08: #18360#18,36020262026-10-20: #19097#19,0972026

Rank in USA: #2,757 (Jan 2020) · #3,650 (Jan 2021) · #4,689 (Jan 2022) · #5,407 (Dec 2022) · #5,026 (Jul 2023) · #4,280 (Jan 2024) · #1,832 (Mar 2026) · #3,119 (Aug 2026) · #3,432 (Oct 2026) · #3,561 (Oct 2026)

Key ratios

market cap and latest results
P/E ratio
n/m (loss)
Price / sales
—
Price / book
0.6×
Free cash flow yield
-70.2%
Net margin
—
Operating margin
—
Return on equity
-53.2%
Liabilities / assets
12.3%
Net debt
$4M
Revenue growth
-77.7%
R&D / revenue
4142.0%
Profit per employee
$-2.2 M

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2018: revenue $5M, net income $-56M$5MFY18Fiscal year ending Dec 2019: revenue —, net income $-71M—FY19Fiscal year ending Dec 2020: revenue $4M, net income $-111M$4MFY20Fiscal year ending Dec 2021: revenue $1M, net income $-46M$1MFY21Fiscal year ending Dec 2022: revenue —, net income $-42M—FY22Fiscal year ending Dec 2023: revenue —, net income $-45M—FY23Fiscal year ending Dec 2024: revenue —, net income $-40M—FY24Fiscal year ending Dec 2025: revenue —, net income $-79M—FY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025——$-85M$-79M—
Dec 2024——$-49M$-40M—
Dec 2023——$-45M$-45M—
Dec 2022——$-40M$-42M—
Dec 2021$1M-77.7%$-56M$-46M-5186.4%
Dec 2020$4M—$-123M$-111M-2824.1%
Dec 2019——$-77M$-71M—
Dec 2018$5M—$-57M$-56M-1155.0%

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-64M$0M$-65M$-5.90—
Dec 2024$-42M$0M$-42M$-3.68—
Dec 2023$-36M$0M$-36M$-10.31—
Dec 2022$-38M$0M$-38M$-10.15—
Dec 2021$-48M$0M$-48M$-11.15—
Dec 2020$-100M$0M$-100M$-1.42—
Dec 2019$-46M$3M$-48M$-1.12—
Dec 2018$-30M$2M$-32M$-0.98—

Quarterly results

USD · three months to · source: SEC filings
RevenueNet income
Three months to Dec 2024 (from the annual report): revenue —, net income $-10M—Dec ’24Three months to Mar 2025: revenue —, net income $-17M—Mar ’25Three months to Jun 2025: revenue —, net income $-18M—Jun ’25Three months to Sep 2025: revenue —, net income $-23M—Sep ’25Three months to Dec 2025 (from the annual report): revenue —, net income $-21M—Dec ’25Three months to Mar 2026: revenue —, net income $-23M—Mar ’26Three months to Jun 2026: revenue —, net income $-35M—Jun ’26Three months to Sep 2026: revenue —, net income $-38M—Sep ’26

Latest quarter to Sep 2026: revenue —, net income $-38M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.

SEC filings

Official filings of Corbus Pharmaceuticals Holdings, Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
—
Operating income
$-85 M
Net income
$-79 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$168 M
Total liabilities
$21 M
Total equity
$148 M

As of December-2025

Top 100 institutional investors in Corbus Pharmaceuticals Holdings, Inc.#

As of Sep 30, 2026
120 institutions held 17.6 M shares (about 85.5% of the shares outstanding) on Sep 30, 2026. The ten largest hold 61.5%. Source: SEC Form 13F filings, filed through Nov 17, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 25 largest institutional investors in Corbus Pharmaceuticals Holdings, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1Cormorant Asset Management, LP2,344,9710 (0.00%)11.38%$16 MNov 16, 2026
2Ra Capital Management, L.P.1,914,788New9.29%$13 MNov 16, 2026
3BlackRock, Inc.1,749,919+418,784 (+31.46%)8.49%$12 MNov 13, 2026
4MPM Bioimpact LLC1,667,272New8.09%$11 MNov 16, 2026
5Orbimed Advisors LLC1,665,656-71,631 (-4.12%)8.08%$11 MNov 16, 2026
6Jones Hill Capital LP886,428+232,856 (+35.63%)4.30%$6 MNov 13, 2026
7Sio Capital Management, LLC766,364New3.72%$5 MNov 16, 2026
8Vanguard Capital Management LLC750,276-10,664 (-1.40%)3.64%$5 MNov 13, 2026
9Caption Management, LLC474,599+446,747 (+1604.00%)2.30%$3 MNov 16, 2026
10Geode Capital Management, LLC450,729+27,355 (+6.46%)2.19%$3 MNov 6, 2026
11AQR Capital Management LLC335,051New1.63%$2 MNov 16, 2026
12Marshall Wace, LLP308,138+228,807 (+288.42%)1.50%$2 MNov 13, 2026
13State Street Corp261,626+6,954 (+2.73%)1.27%$2 MNov 12, 2026
14Dimensional Fund Advisors LP210,313+20,099 (+10.57%)1.02%$1 MNov 4, 2026
15ADAR1 Capital Management, LLC195,469-226,318 (-53.66%)0.95%$1 MNov 16, 2026
16Exome Asset Management LLC190,714+5,800 (+3.14%)0.93%$1 MNov 16, 2026
17Susquehanna International Group, LLP183,420-109,783 (-37.44%)0.89%$1 MNov 16, 2026
18MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.181,102+29,462 (+19.43%)0.88%$1 MNov 16, 2026
19Prosight Management, LP168,383-481,617 (-74.09%)0.82%$1 MNov 13, 2026
20UBS Group AG130,052+81,255 (+166.52%)0.63%$1 MNov 10, 2026
21Goldman Sachs Group Inc128,008+65,145 (+103.63%)0.62%$1 MNov 16, 2026
22Northern Trust Corp127,316+2,410 (+1.93%)0.62%$1 MNov 16, 2026
23FMR LLC126,922+118,271 (+1367.14%)0.62%$1 MNov 10, 2026
24Vanguard Fiduciary Trust Co118,903+6,506 (+5.79%)0.58%$1 MNov 13, 2026
25Vanguard Portfolio Management LLC117,622+6,320 (+5.68%)0.57%$1 MNov 13, 2026
Show all 100: investors 26 to 100
Institutional investors 26 to 100 in Corbus Pharmaceuticals Holdings, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
26Nuveen, LLC115,592+93,284 (+418.16%)0.56%$1 MNov 10, 2026
27Susquehanna Portfolio Strategies, LLC97,371+21,392 (+28.16%)0.47%$1 MNov 16, 2026
28Stonepine Capital Management, LLC95,000-330,000 (-77.65%)0.46%$1 MNov 13, 2026
29Renaissance Technologies LLC94,900-15,922 (-14.37%)0.46%$1 MNov 12, 2026
30Morgan Stanley93,085+72,992 (+363.27%)0.45%$1 MNov 13, 2026
31Point72 Asset Management, L.P.89,312New0.43%$1 MNov 16, 2026
32HSBC Holdings PLC87,173+31,949 (+57.85%)0.42%$1 MNov 16, 2026
33Advisory Services Network, LLC85,351-4,600 (-5.11%)0.41%$1 MNov 13, 2026
34DAFNA Capital Management LLC83,248-24,525 (-22.76%)0.40%$1 MNov 16, 2026
35Millennium Management LLC81,269+69,831 (+610.52%)0.39%$1 MNov 16, 2026
36XTX Topco Ltd79,952+12,298 (+18.18%)0.39%$1 MNov 16, 2026
37BNP Paribas Financial Markets78,274+154 (+0.20%)0.38%$1 MNov 12, 2026
38Doliver Advisors, LP75,975New0.37%$1 MOct 1, 2026
39Walleye Capital LLC75,795New0.37%$1 MNov 13, 2026
40Charles Schwab Investment Management Inc64,831+9,376 (+16.91%)0.31%$0 MNov 16, 2026
41Rangeley Capital, LLC61,400+17,400 (+39.55%)0.30%$0 MNov 16, 2026
42Verdad Advisers, LP60,566-3,037 (-4.77%)0.29%$0 MNov 16, 2026
43Simplex Trading, LLC47,857New0.23%$0 MNov 4, 2026
44Bank of New York Mellon Corp45,2820 (0.00%)0.22%$0 MNov 5, 2026
45D. E. Shaw & Co., Inc.39,502New0.19%$0 MNov 16, 2026
46Driehaus Capital Management LLC38,9770 (0.00%)0.19%$0 MNov 16, 2026
47Panagora Asset Management Inc35,505+19,418 (+120.71%)0.17%$0 MNov 12, 2026
48LMR Partners LLP35,5000 (0.00%)0.17%$0 MNov 16, 2026
49Barclays PLC35,144+27,142 (+339.19%)0.17%$0 MNov 6, 2026
50Cantor Fitzgerald, L. P.30,000-50,196 (-62.59%)0.15%$0 MNov 16, 2026
51Velan Capital Investment Management LP30,000+4,000 (+15.38%)0.15%$0 MNov 16, 2026
52Bank Of America Corp /de/29,641+16,387 (+123.64%)0.14%$0 MNov 16, 2026
53Sectoral Asset Management Inc28,000+8,000 (+40.00%)0.14%$0 MNov 13, 2026
54Pale Fire Capital SE27,300+2,999 (+12.34%)0.13%$0 MNov 13, 2026
55American Century Companies Inc26,976+4,469 (+19.86%)0.13%$0 MNov 12, 2026
56Engineers Gate Manager LP26,454-3,346 (-11.23%)0.13%$0 MNov 16, 2026
57Price T Rowe Associates Inc /MD/26,2710 (0.00%)0.13%$0 MNov 16, 2026
58Quadrature Capital Ltd20,796+8,597 (+70.47%)0.10%$0 MNov 13, 2026
59Rhumbline Advisers19,742-721 (-3.52%)0.10%$0 MNov 10, 2026
60Susquehanna Fundamental Investments, LLC18,8520 (0.00%)0.09%$0 MNov 16, 2026
61Mariner, LLC17,906+6,270 (+53.88%)0.09%$0 MNov 12, 2026
62Jane Street Group, LLC15,537-123,596 (-88.83%)0.08%$0 MNov 12, 2026
63Squarepoint Ops LLC14,218New0.07%$0 MNov 9, 2026
64Sig Brokerage, LP14,200New0.07%$0 MNov 16, 2026
65Ieq Capital, LLC14,037New0.07%$0 MNov 10, 2026
66Deutsche Bank AG\14,023-2,048 (-12.74%)0.07%$0 MNov 6, 2026
67Canada Pension Plan Investment Board12,4000 (0.00%)0.06%$0 MNov 16, 2026
68Aigen Investment Management, LP10,262New0.05%$0 MNov 16, 2026
69UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC9,174+7,950 (+649.51%)0.04%$0 MNov 16, 2026
70Jpmorgan Chase & Co8,552+1,698 (+24.77%)0.04%$0 MNov 12, 2026
71Vanguard Global Advisers, LLC8,467+3,772 (+80.34%)0.04%$0 MNov 13, 2026
72New York State Common Retirement Fund6,6000 (0.00%)0.03%$0 MNov 17, 2026
73Police & Firemen's Retirement System of New Jersey5,4800 (0.00%)0.03%$0 MNov 9, 2026
74Citigroup Inc4,806-6,513 (-57.54%)0.02%$0 MNov 4, 2026
75Royal Bank Of Canada4,465+802 (+21.89%)0.02%$0 MNov 16, 2026
76Tower Research Capital LLC (TRC)4,319+3,385 (+362.42%)0.02%$0 MNov 16, 2026
77Arax Advisory Partners3,450+3,447 (+114900.00%)0.02%$0 MNov 12, 2026
78Wells Fargo & Company/mn3,387-10,449 (-75.52%)0.02%$0 MNov 16, 2026
79Federation des caisses Desjardins du Quebec2,000New0.01%$0 MNov 16, 2026
80Global Retirement Partners, LLC1,8000 (0.00%)0.01%$0 MNov 10, 2026
81Russell Investments Group, Ltd.1,623-137 (-7.78%)0.01%$0 MNov 6, 2026
82Legal & General Group Plc1,5960 (0.00%)0.01%$0 MNov 16, 2026
83Atlantic Private Wealth, LLC1,500+1,000 (+200.00%)0.01%$0 MNov 9, 2026
84Ameritas Investment Partners, Inc.1,4940 (0.00%)0.01%$0 MNov 13, 2026
85JTC Employer Solutions Trustee Ltd1,1060 (0.00%)0.01%$0 MNov 9, 2026
86Pinnacle Wealth Planning Services, Inc.9490 (0.00%)0.00%$0 MOct 27, 2026
87PNC Financial Services Group, Inc.790New0.00%$0 MNov 6, 2026
88Versant Capital Management, Inc6010 (0.00%)0.00%$0 MOct 2, 2026
89Allworth Financial LP591New0.00%$0 MNov 17, 2026
90GAMMA Investing LLC556+220 (+65.48%)0.00%$0 MOct 8, 2026
91Sterling Capital Management LLC325-7 (-2.11%)0.00%$0 MOct 22, 2026
92IFP Advisors, Inc295New0.00%$0 MOct 16, 2026
93EverSource Wealth Advisors, LLC277+204 (+279.45%)0.00%$0 MNov 4, 2026
94Osaic Holdings, Inc.261-1 (-0.38%)0.00%$0 MNov 12, 2026
95Nisa Investment Advisors, LLC259-28 (-9.76%)0.00%$0 MOct 20, 2026
96SJS Investment Consulting Inc.216New0.00%$0 MOct 26, 2026
97Golden State Wealth Management, LLC198+125 (+171.23%)0.00%$0 MNov 2, 2026
98Farther Finance Advisors, LLC170New0.00%$0 MOct 8, 2026
99Parkside Financial Bank & Trust155New0.00%$0 MOct 27, 2026
100Federated Hermes, Inc.123-232 (-65.35%)0.00%$0 MNov 12, 2026

All 120 institutional investors, with who bought and sold →

Mutual funds holding Corbus Pharmaceuticals Holdings, Inc.#

74 funds hold shares worth $32 M (about 17.0% of the company). Since their previous reports 56 added shares and 5 sold, buying $10 M net.
Mutual funds holding Corbus Pharmaceuticals Holdings, Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 abrdn Healthcare Investorsabrdn Inc.778,031$7 M3.8%0.54%no changeJun 30, 2026
🇺🇸 abrdn Life Sciences Investorsabrdn Inc.543,719$5 M2.6%0.74%no changeJun 30, 2026
🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc.533,575$5 M2.6%<0.01%no changeJun 30, 2026
🇺🇸 iShares Russell 2000 ETFBlackRock Fund Advisors406,966$4 M2.0%<0.01%newJun 30, 2026
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.208,310$2 M1.0%<0.01%+17%Jun 30, 2026
🇺🇸 Fidelity Small Cap Index FundFidelity Management & Research Company LLC179,556$2 M0.87%<0.01%newJul 31, 2026
🇺🇸 iShares Russell 2000 Value ETFBlackRock Fund Advisors157,182$1 M0.76%0.01%newJun 30, 2026
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC83,288$1 M0.40%<0.01%−1.3%May 31, 2026
🇺🇸 Dimensional U.S. Small Cap ETFDimensional Fund Advisors LP58,383$1 M0.28%<0.01%no changeJul 31, 2026
🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors55,352$1 M0.27%0.03%+34%Jun 30, 2026
🇺🇸 Schwab Small-Cap Index FundCharles Schwab Investment Management, Inc.39,702$0 M0.19%<0.01%newJul 31, 2026
🇺🇸 Master Small Cap Index SeriesBlackRock Advisors, LLC30,772$0 M0.15%<0.01%newJun 30, 2026
🇺🇸 U.S. Micro Cap PortfolioDimensional Fund Advisors LP31,546$0 M0.15%<0.01%+92%Jul 31, 2026
🇺🇸 U.S. Small Cap PortfolioDimensional Fund Advisors LP26,811$0 M0.13%<0.01%−17%Jul 31, 2026
🇺🇸 Fidelity Small Cap Value Index FundFidelity Management & Research Company LLC23,002$0 M0.11%<0.01%newJun 30, 2026
🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC27,193$0 M0.13%<0.01%no changeMay 31, 2026
🇺🇸 Nuveen Small Cap Blend Index FundTeachers Advisors, LLC22,308$0 M0.11%<0.01%newJul 31, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC23,576$0 M0.11%<0.01%+7.5%May 31, 2026
🇺🇸 Schwab Total Stock Market Index FundCharles Schwab Investment Management, Inc.20,000$0 M0.10%<0.01%newJul 31, 2026
🇺🇸 Avantis U.S. Small Cap Equity ETFAmerican Century ETF Trust22,053$0 M0.11%<0.01%+46%May 31, 2026
🇺🇸 EQ/2000 Managed Volatility PortfolioEquitable Investment Management Group, LLC17,778$0 M0.09%<0.01%newJun 30, 2026
🇺🇸 Goldman Sachs Absolute Return Tracker FundGoldman Sachs Asset Management, L.P.17,490$0 M0.08%<0.01%+218%Jun 30, 2026
🇺🇸 LVIP State Street Small-Cap Index FundLincoln Financial Investments Corporation12,700$0 M0.06%<0.01%newJun 30, 2026
🇺🇸 T. Rowe Price Extended Equity Market Index FundT. Rowe Price Associates, Inc.12,572$0 M0.06%<0.01%no changeJun 30, 2026
🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc.11,420$0 M0.06%<0.01%no changeJun 30, 2026
🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC12,746$0 M0.06%<0.01%+103%May 31, 2026
🇺🇸 U.S. Vector Equity PortfolioDimensional Fund Advisors LP10,512$0 M0.05%<0.01%+344%Jul 31, 2026
🇺🇸 Small Cap Index FundNorthern Trust Investments, Inc.8,618$0 M0.04%<0.01%newJun 30, 2026
🇺🇸 Fidelity ZERO Total Market Index FundFidelity Management & Research Company LLC8,208$0 M0.04%<0.01%no changeJul 31, 2026
🇺🇸 VIP Disciplined Small Cap PortfolioFidelity Management & Research Company LLC7,783$0 M0.04%0.01%newJun 30, 2026
🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc.7,635$0 M0.04%<0.01%−29%Jun 30, 2026
🇺🇸 Global X Russell 2000 ETFGlobal X Management Company LLC7,862$0 M0.04%<0.01%newJul 31, 2026
🇺🇸 Fidelity ZERO Extended Market Index FundFidelity Management & Research Company LLC6,112$0 M0.03%<0.01%+12%Jul 31, 2026
🇺🇸 EQ/AB Small Cap Growth PortfolioEquitable Investment Management Group, LLC4,840$0 M0.02%<0.01%newJun 30, 2026
🇺🇸 EQ/Small Company Index PortfolioEquitable Investment Management Group, LLC4,840$0 M0.02%<0.01%newJun 30, 2026
🇺🇸 Small-Cap Index PortfolioPacific Life Fund Advisors LLC4,668$0 M0.02%<0.01%newJun 30, 2026
🇺🇸 iShares Russell Small/Mid-Cap Index FundBlackRock Advisors, LLC4,734$0 M0.02%<0.01%newJul 31, 2026
🇺🇸 Dimensional U.S. Core Equity 2 ETFDimensional Fund Advisors LP4,229$0 M0.02%<0.01%no changeJul 31, 2026
🇺🇸 State Street Small/mid Cap Equity Index PortfolioSSGA Funds Management, Inc.4,000$0 M0.02%<0.01%newJun 30, 2026
🇺🇸 Small Cap Index TrustJohn Hancock Variable Trust Advisers LLC3,964$0 M0.02%<0.01%newJun 30, 2026
🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC3,744$0 M0.02%0.02%+30%Jun 30, 2026
🇺🇸 ATM Small Cap Managed Volatility PortfolioEquitable Investment Management Group, LLC3,660$0 M0.02%<0.01%newJun 30, 2026
🇺🇸 NVIT Small Cap Index FundNATIONWIDE FUND ADVISORS3,621$0 M0.02%<0.01%newJun 30, 2026
🇺🇸 JNL/DFA U.S. Small Cap FundJackson National Asset Management, LLC3,305$0 M0.02%<0.01%+121%Jun 30, 2026
🇺🇸 BlackRock Advantage SMID Cap V.I. FundBlackRock Advisors, LLC3,063$0 M0.01%0.02%newJun 30, 2026
🇺🇸 BlackRock Advantage Small Cap Growth FundBlackRock Funds2,685$0 M0.01%<0.01%newJun 30, 2026
🇺🇸 Fidelity Flex Small Cap Index FundFidelity Management & Research Company LLC2,761$0 M0.01%<0.01%+16%Jul 31, 2026
🇺🇸 DWS Small Cap Index VIPDWS Investment Management Americas, Inc.2,572$0 M0.01%<0.01%newJun 30, 2026
🇺🇸 1290 VT Small Cap Value PortfolioEquitable Investment Management Group, LLC2,565$0 M0.01%<0.01%newJun 30, 2026
🇺🇸 Dimensional US Core Equity Market ETFDimensional Fund Advisors LP2,680$0 M0.01%<0.01%newJul 31, 2026
🇺🇸 T. Rowe Price Small-Cap Index FundT. Rowe Price Associates, Inc.2,511$0 M0.01%<0.01%newJun 30, 2026
🇺🇸 U.S. Core Equity 1 PortfolioDimensional Fund Advisors LP2,374$0 M0.01%<0.01%no changeJul 31, 2026
🇺🇸 BlackRock Small Cap Index V.I. FundBlackRock Advisors, LLC2,215$0 M0.01%<0.01%newJun 30, 2026
🇺🇸 U.S. Core Equity 2 PortfolioDimensional Fund Advisors LP1,951$0 M<0.01%<0.01%no changeJul 31, 2026
🇺🇸 SA Small Cap Index PortfolioSunAmerica Asset Management, LLC1,928$0 M<0.01%<0.01%newJul 31, 2026
🇺🇸 Victory Extended Market Index FundVictory Capital Management Inc.1,913$0 M<0.01%<0.01%+6.9%Jul 31, 2026
🇺🇸 Nationwide Fundamental All Cap Equity PortfolioNATIONWIDE FUND ADVISORS1,868$0 M<0.01%<0.01%newJul 31, 2026
🇺🇸 Dimensional US Core Equity 1 ETFDimensional Fund Advisors LP1,791$0 M<0.01%<0.01%no changeJul 31, 2026
🇺🇸 CVT Russell 2000 Small Cap Index PortfolioCalvert Research and Management1,494$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 Nationwide Small Cap Index FundNATIONWIDE FUND ADVISORS1,452$0 M<0.01%<0.01%newJul 31, 2026
🇺🇸 Venerable Small Cap Index FundVenerable Investment Advisers, LLC1,314$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 PD Small-Cap Value Index PortfolioPacific Life Fund Advisors LLC1,297$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 SmallCap Value Fund IIPrincipal Global Investors, LLC1,340$0 M<0.01%<0.01%newJul 31, 2026
🇺🇸 U.S. Social Core Equity 2 PortfolioDimensional Fund Advisors LP1,300$0 M<0.01%<0.01%no changeJul 31, 2026
🇺🇸 LVIP Dimensional U.S. Core Equity 2 FundLincoln Financial Investments Corporation1,173$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 VIP Extended Market Index PortfolioFidelity Management & Research Company LLC1,143$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 Small-Cap Equity PortfolioPacific Life Fund Advisors LLC715$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 EQ/Franklin Small Cap Value Managed Volatility PortfolioEquitable Investment Management Group, LLC645$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 State Street Total Return V.I.S. FundSSGA Funds Management, Inc.416$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 VIP Total Market Index PortfolioFidelity Management & Research Company LLC391$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 Total Stock Market Index TrustJohn Hancock Variable Trust Advisers LLC366$0 M<0.01%<0.01%+4.6%Jun 30, 2026
🇺🇸 Dimensional US Vector Equity ETFDimensional Fund Advisors LP201$0 M<0.01%<0.01%newJul 31, 2026
🇺🇸 State Street Balanced Index FundSSGA Funds Management, Inc.113$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 Knights of Columbus U.S. ALL CAP INDEX FUNDKnights of Columbus Asset Advisors LLC99$0 M<0.01%<0.01%+7.6%Jul 31, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 74 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at Corbus Pharmaceuticals Holdings, Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$126 K
3 purchases, 1 insider
Sold, 12 months
$2.7 M
14 sales, 10 insiders
Net, 12 months
-$2.6 M
open market only
Insiders on file
26
since
$23.3 M-$3.8 M$0Jan 2024: bought $9.1 M (14 trades), sold $0 (0 trades)Jan 24Feb 2024: bought $14.3 M (1 trades), sold $0 (0 trades)Mar 2024: bought $23.3 M (10 trades), sold $0 (0 trades)MarJun 2024: bought $0 (0 trades), sold $3.8 M (12 trades)Sep 2024: bought $7.0 M (6 trades), sold $0 (0 trades)SepFeb 2025: bought $0 (0 trades), sold $87 K (2 trades)Mar 2025: bought $0 (0 trades), sold $43 K (1 trades)MarMay 2025: bought $0 (0 trades), sold $31 K (2 trades)Oct 2025: bought $0 (0 trades), sold $714 K (4 trades)OctDec 2025: bought $0 (0 trades), sold $344 K (1 trades)Feb 2026: bought $0 (0 trades), sold $197 K (5 trades)FebMar 2026: bought $0 (0 trades), sold $51 K (1 trades)Jun 2026: bought $101 K (2 trades), sold $73 K (3 trades)JunAug 2026: bought $25 K (1 trades), sold $292 K (2 trades)Sep 2026: bought $0 (0 trades), sold $16 K (1 trades)SepOct 2026: bought $0 (0 trades), sold $1.7 M (1 trades)
Bought (open market)Sold (open market)Hover a month for the totals
Corbus Pharmaceuticals Holdings, Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Cormorant Asset Management, LPFormer 10% OwnerSellindirect-425,000$4.101$1.7 M1.92 MForm 4
filed Yong BenDirectorSell10b5-1 plan-2,000$7.840$16 K9,383Form 4
filed Leonardo Viana NicacioChief Medical OfficerGrant or award+58,333——58,333Form 4
filed Nishant C. SaxenaChief Business OfficerBuy+2,600$9.630$25 K77,900Form 4
filed Sean F. MoranChief Financial OfficerSell10b5-1 plan-12,000$10.08$121 K84,694Form 4
filed Yuval CohenChief Executive Officer, DirectorSell10b5-1 plan-17,000$10.08$171 K157,316Form 4
filed Winston KungDirectorSell10b5-1 plan-2,026$7.910$16 K12,140Form 4
filed John Kenneth JenkinsDirectorSell10b5-1 plan-4,800$7.910$38 K3,833Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Corbus Pharmaceuticals Holdings, Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
3.2 M
18.4% of shares · 3.48 days to cover
Shares sold short, last 24 reportsAll stocks →

Fails to deliver

  • : 231 shares at $4.46
  • : 412 shares at $4.33
  • : 1,432 shares at $5.49
  • : 1,407 shares at $5.78
  • : 262 shares at $5.85

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Corbus Pharmaceuticals Holdings, Inc. scorecard#

Passes 3 of the 12 checks that could be worked out: strongest in valuation (1 of 4), weakest in profitability (0 of 3). Fiscal year 2025; market cap of Oct 20, 2026.

  • Valuation1 of 4
    • ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
    • ✓Price to book below its peers' median0.6×Price to book 0.6× against Biotechnology's median of 2.9×.
    • –Price to sales below its peers' medianNo Price to sales on file.
    • ✗Free cash flow yield above 5%-70.2%Free cash flow is -70.2% of the market value.
    • ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth1 of 2
    • –Revenue grew in the newest yearRevenue of the year before is not on file.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • ✗Earnings per share grew in the newest year-5.90 vs -3.68Diluted EPS -5.90 in fiscal 2025 against -3.68 the year before (report's currency).
    • ✓Net income higher than five years earlier-$79 M-$79 M in fiscal 2025 against -$111 M in 2020.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability0 of 3
    • ✗Profitable in the newest year-$79 MNet income -$79 M in fiscal 2025.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
    • –Operating margin above its peers' medianNo operating margin on file.
    • ✗Return on equity above 15%-54.2%-54.2% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial health1 of 2
    • ✓Short-term assets cover short-term liabilities8.1×Current ratio 8.07 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
  • Shareholder returns0 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✗Share count up no more than 2% in a year22.0%Diluted shares up 22.0% in fiscal 2025.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Corbus Pharmaceuticals Holdings, Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Corbus Pharmaceuticals Holdings, Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020FY 2019to Dec 31, 2019FY 2018to Dec 31, 2018FY 2017to Dec 31, 2017FY 2016to Dec 31, 2016
Income statement
Revenue———00.93.9364.82.41.9
Research and development703231r16369890492615
General and administrative151614r19202824139.06.5
Operating expenses854945r4057127113623522
Operating income−85−49−45r−40−56−123−77−57−33−20
Interest and finance income——————1.21.0——
Interest expense and finance costs01.93.9r3.12.71.10—0.00.0
Net interest income——−2.9−2.1−1.8−1.01.2———
Other non-operating income (expense)6.88.50.5r−2.510125.71.10.1−0.0
Income tax00————————
Net income including minority interests−79−40−45r−42−46−111————
Minority interests' share of net income−79−40————————
Net income attributable to shareholders−79−40−45r−42−46−111−71−56−32−20
Earnings per share, basic-5.90-3.68-10.31-10.15-11.15r-1.42-1.12-0.98-0.65-0.49
Earnings per share, diluted-5.90-3.68-10.31-10.15-11.15r-1.42-1.12-0.98-0.65-0.49
Shares, weighted average (basic)13114.34.24.1r78————
Shares, weighted average (diluted)13114.34.24.1r7864575041
Balance sheet
Cash and cash equivalents281714r17258532426315
Short-term investments1351327.2r4273—————
Other current assets3.03.62.4r0.82.43.73.72.52.80.9
Current assets16715324r601009238446617
Property, plant and equipment0.20.41.0r1.62.44.15.12.71.40.4
Right-of-use (leased) assets1.12.13.1r3.94.65.25.8———
Total assets16815628r6610810249476718
Accounts payable2.24.83.2r2.21.87.4116.33.13.4
Debt due within a year——162.83.1—————
Current liabilities211232r13173235188.28.9
Long-term debt——0161618————
Lease liabilities (non-current)01.63.2r4.76.07.18.11.4——
Total liabilities211335r33395743199.29.0
Retained earnings−555−477−437r−392−350−304−193−121−66−33
Shareholders' equity148142−6.9r33r69456.228588.9
Total liabilities and equity16815628r6610810249476718
Shares outstanding18124.44.24.2r9965575645
Cash-flow statement
Depreciation and amortization0.20.60.6r0.81.01.10.70.50.30.1
Share-based compensation6.36.13.5r5.79.512127.65.73.2
Cash from operating activities−64−42−36r−38−48−100−46−30−28−14
Capital expenditure−0.000−0.0−0.1−0.5−2.7−2.3−0.7−0.4
Cash from investing activities−1.6−12136r30−73−0.5−2.7−2.3−0.7−0.4
Debt issued———1.4—19————
Debt repaid———−1.5——————
Shares issued771820.1r—6314241127917
Cash from financing activities77167−2.8r−0.56115538117617
Change in cash113.5−3.3r−8.0−6155−10.0−2148—
Report10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

Where Corbus Pharmaceuticals Holdings, Inc. operates: 3 countries#

Countries where the company has its headquarters, an office, subsidiaries, a branch or reported revenue. 3 subsidiaries on file.

Corbus Pharmaceuticals Holdings, Inc.: countries of operation
CountryPresenceRevenue there
🇺🇸 USAHeadquarters2 offices1 subsidiary—
🇦🇺 Australia1 subsidiary—
🇬🇧 UK1 subsidiary—

Source: GLEIF legal-entity register, SEC Exhibit 21 and annual reports, office addresses on file. A country without subsidiaries or offices on record is not listed even if the company sells there. How presence is decided

Executive pay at Corbus Pharmaceuticals Holdings, Inc.#

From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.

CEO total pay, fiscal 2025
$3.8 M
Dr. Cohen
Other top executives, average
$1.8 M
the CEO earned 2.1× this
$100 invested is now
$244
Corbus Pharmaceuticals Holdings, Inc.: executive pay by fiscal year
Fiscal yearCEO total payActually paidOther executives, average$100 invested
2025Dr. Cohen$3.8 M$2.6 M$1.8 M$244
2024Dr. Cohen$4.2 M$4.1 M$2.7 M$354
2023Dr. Cohen$1.1 M$1.4 M$779 K$181

Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025

Events at Corbus Pharmaceuticals Holdings, Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.

Directors and officers 7 · Material agreement 3 · Shareholder vote 2 · Results announced 8

Corbus Pharmaceuticals Holdings, Inc.: events reported to the SEC
FiledWhat happenedFiling
Results announced8-K
Results announced8-K
Material agreement8-K
Directors and officersMaterial agreement8-K
Directors and officersShareholder vote8-K
Results announced8-K
Directors and officers8-K
Directors and officers8-K
Results announced8-K
Directors and officers8-K
Results announced8-K
Material agreement8-K
Results announced8-K
Shareholder vote8-K
Results announced8-K
Directors and officers8-K
Directors and officers8-K
Results announced8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Nov 10, 2026

Lobbying by Corbus Pharmaceuticals Holdings, Inc.#

$146 K spent on lobbying the US Congress and federal agencies in 2020, most often on health issues.

Lobbying, 2020
$146 K
#874 among companies on value.today
Own lobbyists
No
only outside firms
Firms hired
1
in 2020
2026 so far
—
  • Health Issues4 reports

Lobbying firms hired in 2020

East End Group, LLC $146 K

Corbus Pharmaceuticals Holdings, Inc.: lobbying spending by year
YearSpendingOwn lobbyistsReports
2020$146 K—4
2019$180 K—4
2018$60 K—2

Source: Lobbying Disclosure Act reports (Form LD-2). Filed as “Corbus Pharmaceuticals Holdings, Inc”. Reports round to the nearest $10,000, and one of less than $5,000 counts as zero

H-1B hiring at Corbus Pharmaceuticals Holdings, Inc.#

3 labor condition applications certified in fiscal 2022 for 3 positions, at a median wage of $96 K a year.

Certified, FY2022
3
#1,520 among companies on value.today
Worker positions
3
Median wage offered
$96 K
a year, full-time
Applications filed
3
Corbus Pharmaceuticals Holdings, Inc.: most frequent H-1B job titles in fiscal 2022
Job titlePositionsMedian wage offered
Scientist IChemists3$96 K

Where: Norwood, MA 3

Corbus Pharmaceuticals Holdings, Inc.: labor condition applications by fiscal year
Fiscal yearCertifiedPositionsMedian wageFiled
FY202233$96 K3
FY202011$110 K1

Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as Corbus Pharmaceuticals, Inc.

Layoffs at Corbus Pharmaceuticals Holdings, Inc.#

From US state WARN notices and SEC 8-K restructuring filings, newest first.

People, last 12 months
0
0 notices and filings
People, all years
89
2020–2020
Latest
89 people
2020-10-08
Corbus Pharmaceuticals Holdings, Inc.: people laid off by year and month
YearJanFebMarAprMayJunJulAugSepOctNovDecTotal
2020·········89··89
Corbus Pharmaceuticals Holdings, Inc.: latest layoffs
AnnouncedPeopleKindWhereSource
89 people (54% of workforce)Restructuring planSEC 8-K“Under this plan, the Company plans to reduce its 2020 workforce by 54%, including 89 employees that will be terminated, resulting in a workforce of 76 employees.”Filing

Source: State WARN notices and SEC 8-K item 2.05

How Corbus Pharmaceuticals Holdings, Inc. compares in Biotechnology

  • Market cap$92 M · higher than 35% of 726
  • Revenue growth-77.7% · higher than 7% of 438
  • Price / book0.6× · lower than 89% of 534
  • FCF yield-70.2% · higher than 17% of 449

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
Corbus Pharmaceuticals Holdings, Inc.🇺🇸$92 M——-77.7%
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 20, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Employees:
As of December 31, 2025
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research, SEC annual report, Wikidata, GLEIF register; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Corbus Pharmaceuticals Holdings, Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Corbus Pharmaceuticals Holdings, Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Corbus Pharmaceuticals Holdings, Inc.? Suggest a correction